Tyra Biosciences, Inc. (TYRA) saw its shares plummet 5.08% during intraday trading on Tuesday, following analyst coverage initiation by Wolfe Research.
Wolfe Research began coverage of the biopharmaceutical company with a "Peer Perform" rating and did not assign a price target. The neutral "Peer Perform" rating suggests the analyst expects the stock to perform in line with its industry peers, which may have disappointed investors hoping for a more bullish outlook.